🎉 Pharmidex Celebrates Scientific Achievement! 🧪
January 27, 2025

We are thrilled to announce that members of the  Pharmidex  team have contributed to groundbreaking research, published in the prestigious journal  International Journal of Molecular Sciences


📄 The paper, titled "Biomass-Derived Nanoporous Carbon Honeycomb Monoliths for Environmental Lipopolysaccharide Adsorption from Aqueous Media", explores innovative solutions for environmental challenges using advanced materials science.


👏 We extend our heartfelt congratulations and gratitude to all the authors for their dedication and hard work in bringing this important research to life.


🔗 Curious about the study? You can read the full article here: Read the Article (https://www.mdpi.com/1422-0067/26/3/952#)

We are proud to support and celebrate cutting-edge science that drives meaningful impact. Let’s continue pushing the boundaries of innovation! 🚀

#Pharmidex #Research #Innovation #Nanotechnology #Sustainability #Science

🚀 Pharmidex at the R&D Society Life Science Workshop!

June 11, 2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN

🔬 Pharmidex at the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium

June 10, 2025
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG

🔬 Pharmidex is proud to contribute to new research!

June 10, 2025
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
More Posts